

23 August, 2023

Dear Customer or Prescriber,

RE: SUPPLY OF

**CELESTONE® CHRONODOSE® Injection**

Betamethasone acetate and Betamethasone sodium phosphate 5.7mg/1mL injection ampoule

Thank you for your patience and support regarding the ongoing supply challenges with CELESTONE CHRONODOSE. We can now advise that availability of CELESTONE CHRONODOSE has improved, and the restriction to supply for patients with specific medical indication has been removed.

At this point we will **not** be able to return to full supply without any restrictions.

We will however, be able to provide our wholesalers with a specific allocation each month. The Organon Customer Service Team will confirm this allocation directly with each customer.

The wellbeing of our patients is always our top priority. Any customer that cannot access stock through their normal channels for the specific indication **for antepartum use in the prevention of respiratory distress syndrome in premature infants prior to 32 weeks of gestation<sup>1</sup>**, can order directly through the Organon Customer Service Team. To do this, please contact Organon Customer Service by e-mail: [customerservice.au@organon.com](mailto:customerservice.au@organon.com)

Should you have any medical questions, please do not hesitate to contact Organon Medical Information on 1800 023 135 or e-mail [dpoc.anz@organon.com](mailto:dpoc.anz@organon.com)

Thank you for your patience and understanding as we work to bring CELESTONE CHRONODOSE back to full market supply.

Kind Regards,



Steve Ireland  
Operations Lead

References. 1. Celestone Chronodose Approved Product Information. [www.organon.com/australia/our-products/](http://www.organon.com/australia/our-products/)